Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
This explicit step requires the program to seek explanations for unusually high or low outcomes on each indicator. The organization should establish a routine process for examining the findings from the latest outcome reports. For example, exhibit 11 compares outcomes for three family service units on one particular demographic characteristic. The two outlying values circled in the exhibit indicate unusual outcomes that a program manager will likely want to investigate. | NHS National Institute for Health and Clinical Excellence Issue date March 2010 Neuropathic pain The pharmacological management of neuropathic pain in adults in non-specialist settings NICE clinical guideline 96 Developed by the Centre for Clinical Practice at NICE NICE clinical guideline 96 Neuropathic pain the pharmacological management of neuropathic pain in adults in non-specialist settings Ordering information You can download the following documents from www.nice.org.uk guidance CG96 The full guideline this document - all the recommendations details of how they were developed and reviews of the evidence they were based on. A quick reference guide - a summary of the recommendations for healthcare professionals. Understanding NICE guidance - a summary for patients and carers. For printed copies of the quick reference guide or Understanding NICE guidance phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote N2115 quick reference guide N2116 Understanding NICE guidance . NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales. This guidance represents the view of NICE which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient in consultation with the patient and or guardian or carer and informed by the summary of product characteristics of any drugs they are considering. Implementation of this guidance is the responsibility of local commissioners and or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance in their local context in light of their duties to avoid unlawful discrimination
